Ouro Medicines’ drugs deplete disease-driving ... Monograph Capital founded the startup in partnership with GSK. 3D medical animation services have emerged as a groundbreaking tool in the ...

California-based immunology start-up Ouro Medicines, which is developing immune reset therapeutics for people living with chronic immune-mediated diseases, has announced its launch with $120 million ...

Based in San Francisco and launched in 2025, Ouro was founded by Monograph Capital in partnership with GSK. Ouro is also backed by leading investors TPG, NEA, and Norwest. For more information ...

SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Ouro Medicines, a biotechnology company ... The company was founded by Monograph Capital in partnership with GSK plc. The Series A was co-led by ...